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Abstract 
Retinoic acid (RA) stimulated the production of erythropoietin (Epo) in a human hepatoma cell line, HepG2 cells. The stimulation was due to 
the accumulation of Epo mRNA. The Epo production in HepG2 cells was also dependent on O2 tension for cell culture but the enhancement of Epo 
production by RA was independent of O2 tension, indicating that RA exerts its effect through a pathway different from 0,. Oral administration of 
RA to the vitamin A-depleted rats elevated the concentration of Epo in serum. These results suggest hat RA up-regulates EPO production in vivo 
as well as in vitro. 
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1. Introduction 
Epo is a major physiological regulator of erythropoi- 
esis [I ,2]. In the fetus, the primary site of Epo production 
is the liver [3] and is replaced by the kidney in adults [4]. 
Hypoxia induces Epo production by increase of Epo 
mRNA [5-lo]. The c&acting sequences of the Epo gene 
responsible for hypoxic induction were identified in a 
promoter region and in a 3’-flanking region [I l-171. 
RA, a derivative of vitamin A, exerts a wide variety of 
effects on vertebrate development, cellular differentia- 
tion and homeostasis. Most effects of RA are caused by 
the transcriptional control of the target genes, which is 
mediated by two classes of nuclear receptors, retinoic 
acid receptors (RAR-a, RAR-p and RAR-y) and reti- 
noid X receptors (RXR-a, RXR-p and RXR-y) [18]. 
RARs and RXRs are members of the steroid/thyroid 
receptor superfamily, and function as ligand-dependent 
transcription factors by binding with the specific re- 
sponse elements of the target genes. Homo- and heterod- 
imers of RARs and RXRs recognize direct repeats of the 
core motif (AGGTCA or its closely related motifs) with 
one, two or five nucleotide space (DR-1, DR-2 and DR- 
5, respectively) [19-231. 
*Corresponding author. Fax: (81) (75) 753 6274. 
Abbreviations: Epo, erythropoietin; RA, retinoic acid; FCS, fetal calf 
serum; PBS, 10 mM phosphate-buffered saline, pH 7.2; EIA, enzyme- 
linked immunoassay; MoAb, monoclonal antibody; RT-PCR, reverse 
transcription-polymerase chain reaction. 
Although the sequence homologous to DR-2 is present 
in the 3’-enhancer egion of Epo gene and the nuclear 
extract of Epo-producing cells contains a protein(s) 
bound to the DR-2 sequence [ 11,121, there is no reports 
showing that RA regulates Epo production. In this 
paper, we have examined the effect of RA on Epo pro- 
duction using human hepatoma cells (HepG2) cultured 
in the retinoid-depleted FCS and vitamin A-depleted 
rats. 
2. Materials and methods 
2.1. Cell culture and others 
HepG2 cells were cultured at 37°C in the minimum essential medium 
supplemented with 10% FCS (M. A. Bioproducts, Walkersville, MD) 
at 2 1% 0*/S% CO,/balance N2 gas in a controlled atmosphere chamber 
(Napco Scientific Co., Tualatin, OR). Retinoid-depleted FCS was pre- 
pared by treatment with charcoal [24]. To deplete intracellular eti- 
noids, after the cells were cultured in the retinoid-depleted FCS for 
three days, the cells were replated at 2 x lo4 cells/cm* and cultured for 
another two days. Experiments were started by the cell culture at 21% 
O2 at 1% 0, in the fresh RA-depleted FCS added at indicated concen- 
trations of RA. All-trans RA, retinol, retinal, and a- or/3-carotene were 
dissolved in ethanol and diluted with the medium ( < 0.1% final ethanol 
contents). To measure the cellular protein, the cells were washed with 
PBS, incubated in 1 ml of 0.1 M HCI for 1 min and then lysed with 
1 ml of 1 M NaOH. Protein in the lysates was determined with commer- 
cial kits (Protein Assay; Bio-Rad Laboratories, Richmond, CA). 
2.2. De novo synthesis of protein and RNA 
The cells precultured to deplete RA in 6-well dishes were incubated 
at 21% 0, or 1% O2 in the RA-depleted FCS containing RA at 0, I, 
and 100 nM. After incubation for 4 h. 50 uCi of l”Slmethionine/ 
[?S]cysteine mixture or [‘Hluridine was added and the ceils were cul- 
tured for 20 h. Incorporation of the radioactive precursors into the 
trichloroacetic acid-soluble fraction was determined. The background 
was assessed by concurrent addition of inhibitors (10 pg/ml of cyclo- 
heximide for protein synthesis or 5 &ml of actinomycin D for RNA 
synthesis). 
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2.3. Sandwich-type enzyme immunoassay of Epo 
We have described a sandwich-type EIA for Epo measurement using 
two MoAb (R2 and R6) that bind Epo at different epitopes [25,26]. 
To measure small amounts of Epo, this EIA was further improved. To 
the 96 well-microtiter plates was added 100 ,~l of the R6 solution (10 
mg/ml in 50 mM sodium carbonate buffer, pH 9.6). After a 2-h incuba- 
tion, the unfixed MoAb was washed with washing buffer (PBS contain- 
ing 0.05% Tween 20 and 0.02% NaN,). To each well was added 100 ,~l 
of the standard recombinant human Epo [27] or sample containing 
0.05% Tween 20 and 1 mM EDTA and the plates were incubated for 
2 h. After washing, 100 ~1 of alkaline phosphatase-linked R2 (0.5 ,q/ml 
in washing buffer) was added and incubated for 2 h to form ternary 
complexes (fixed R6. Epo. R2 linked with alkaline phosphatase). After 
washing, the activity of phosphatase trapped in the microtiter wells was 
measured calorimetrically using coupled enzymes as follows. In this 
method, NADP is dephosphorylated by alkaline phosphatase and the 
resulting NAD is amplified by coupling enzymes, alcohol dehydroge- 
nase and diaphorase. To the washed well was added 100 ,~l of 0.1 M 
diethanolamine buffer, pH 9.5, containing 0.4 M NADP, 2 mM MgCI,, 
and 0.02% NaN,. After incubation for 20 min was added 200 ,uI of the 
enzyme solution containing 0.2 mg/ml alcohol dehydrogenase, 1.6 unit/ 
ml diaphorase, 56 mg/ml ethanol and 350 mg/ml INT violet. The reac- 
tions for amplification were stopped with 50 ~1 of 0.4 M HCl and the 
produced formazan was determined by measuring the absorbency at 
492 nm with an EIA reader. This improved assay measures Epo as low 
as 1 pg/ml. 
2.4. Competitive RT-PCR for Epo transcripts 
To estimate Epo mRNA, the competitive RT-PCR was used [28]. 
Total RNA was prepared by the acid guanidinium isothiocyanate/ 
phenol/chloroform method 1291. Five micrograms of the denatured 
RNA was reverse-transcribed using the Epo-antisense primer (Epo-B; 
5’-AGATGTCATTGCTGGCACTGGAGTGTCCAT-3’) (see Fia. 
3A) [30]. The transcribed Epo cDNA was co-amplified by PCR in the 
presence of various amounts of genomic Epo DNA as a competitor. 
The primers used for amplification were Epo-A, S-GTCGGGCAG- 
CAGGCCGTAGAAGTCTGGCAG-3’ and Epo-B (see Fig. 3A). 
Each of 60 cycles of PCR consisted of incubation for I min at 94°C for 
denaturation, for 2 min at 62°C for annealing, and for 3 min at 72°C 
for elongation. The amplified DNA was fractionated with electrophore- 
sis, stained with ethidium bromide, and analyzed densitometrically. 
3. Results and discussion 
3.1. Effect of RA on Epo production in HepG2 cells 
The presence of retinoids in the intracellular pool and 
in the serum used for cell culture makes it difficult to 
evaluate effect of the exogenous RA on cultured cells. 
We stripped retinoids from FCS with charcoal, and 
precultured the cells in the medium containing retinoid- 
depleted FCS to remove intracellular etinoids before the 
start of the experiment. Fig. 1 shows the Epo production 
in HepG2 cells cultured for 48 h in the untreated or 
retinoid-depleted FCS at 21% 0,. The cells cultured in 
the untreated FCS produced 78 + 6 nglg protein 
(13.3 f 2.2 pg/ml in the medium) and the addition of RA 
at 10 nM slightly stimulated Epo production (1.3-fold 
stimulation). When the cells were cultured in the reti- 
noid-depleted FCS, the production was low but there 
was a distinct stimulation (3-fold enhancement) of Epo 
production by RA. The Epo production in the retinoid- 
depleted FCS plus RA was comparable to that in the 
untreated FCS plus RA. There was no significant differ- 
ence in the total de novo protein synthesis with or with- 
out RA (data not shown). Therefore, the stimulation of 
I 
untreated 
+ 
RA-depleted 
+ 
Fig. 1. RA stimulates Epo production in HepG2 cells. HepG2 cells were 
cultured in the untreated FCS (shaded columns) or RA-depleted FCS 
(white columns) (see section 2 of preparation of RA-depleted cells) at 
21% 0,. Then the cells were cultured in 6-well dishes with or without 
IO nM RA for 48 h. Epo in the culture media and cellular protein were 
determined. Each value is the mean f S.D. in triplicate cultures. 
Epo production by RA is not due to the activation of 
total protein synthesis in the cells. 
Hypoxia is a major inducer of Epo production and the 
3’ enhancer region required for the hypoxic induction 
contains a putative RA-responsive element [l 11. To test 
whether the signal pathway for the stimulation of Epo 
production by RA interacts with that for the induction 
by hypoxia, we compared the effect of RA on Epo pro- 
duction in HepG2 cells at different 0, tensions (21% O2 
and 1% 0,). RA stimulated the Epo production under 
1% 0, as well as 21% 0, (Fig. 2) and the extents of 
induction at different RA concentrations were similar 
under both O2 tensions (Fig. 2, inset). It thus appears 
that RA stimulates Epo production through the pathway 
independent of the hypoxic induction. 
The stimulation of Epo production was detectable at 
0.1 nM RA (P < 0.01) and the maximum enhancement 
was 3-fold (Fig. 2). The concentration (ED,,) of RA 
required for half the maximal effect was 0.7 nM (Fig. 2, 
inset). Retinol and retinal also stimulated Epo produc- 
tion but they were less potent than RA; ED,, values for 
retinol and retinal were 17.8 and 6.3 nM, respectively. 
The effect of retinol and retinal probably results from 
conversion of these retinoids to RA. There was no stim- 
ulation of Epo production by a- or p-carotene. 
3.2. Effect of RA on Epo mRNA contents in HepG2 cells 
Most effects of RA are due to transcriptional control 
of the target genes [18]. We examined the effect of RA 
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Fig. 2. Enhancement of Epo production by RA in HepG2 cells cultured 
under different 0, tensions. After preculture of HepG2 cells to deplete 
RA as described in section 2, the cells were cultured in 6-well dishes in 
the RA-depleted FCS added at the indicated concentrations of RA at 
21% O2 (white bars) or 1% 0, (hatched bars) for 24 h. Epo in the culture 
media and cellular protein were determined. Each value is the 
mean f S.D. in triplicate cultures. In the inset, the amount of Epo 
produced in the cells cultured without RA under each O2 tension is 
defined as 100% and each enhancement of Epo production by RA is 
represented in percent (0, 21% 0,; A, 1% 0,). 
on the Epo mRNA contents by the competitive RT-PCR 
(Fig. 3A). Epo mRNA in the total RNA preparation was 
reverse-transcribed to Epo cDNA. Epo cDNA was am- 
plified by PCR in the presence of various amounts of a 
competitor DNA, the genomic DNA fragment of Epo. 
The amplification yields the DNA fragments with 485 bp 
and 619 bp from Epo cDNA and Epo genomic DNA, 
respectively. The relative intensity of these two amplified 
products depends on the concentration ratios of Epo 
cDNA and Epo genomic DNA in the reaction mixtures 
for amplification, which allows the estimation of Epo 
cDNA. When total RNA was prepared from the cells 
cultured in the presence of 100 nM RA at 1% 02, the 
specific band for Epo cDNA (485 bp) was detected and 
the content of Epo cDNA in the reaction mixture was 
estimated to be 5.0 + 0.2 pg (n = 3; Fig. 3B). When the 
total RNA was prepared from the cells cultured without 
RA, the Epo cDNA content was almost the lower limit 
of detection (1 pg) (data not shown) . These results indi- 
cate that RA stimulates Epo production through accu- 
mulation of Epo mRNA. There was no significant differ- 
ence in the total RNA synthesis in the cells cultured with 
or without RA (data not shown), indicating that RA 
accumulated Epo mRNA in a specific manner. 
The DR-2 sequence (a RA-responsive element) is pres- 
ent in the 3’ flanking region of Epo gene [ 1 l-l 3,16,17]. 
Epo-producing cells express a protein(s) that binds to 
this sequence [11,12]. It is thus likely that the accumula- 
tion of Epo mRNA by RA is caused by the transcrip- 
tional activation of Epo gene due to the interaction of 
RA receptors to the DR-2 sequence, although the possi- 
bility that RA accumulates Epo mRNA through elonga- 
tion of its lifetime has not been excluded. However, Blan- 
chard et al. [l l] have shown that the transient expression 
of the reporter gene linked to the 3’ enhancer region 
containing the DR-2 sequence does not respond to RA 
in Hep3B cells. The inconsistency with our results needs 
to be investigated further. It is noted that during prepa- 
ration of this paper, Fandrey et al. [32] have shown 
thyroid hormone-induced stimulation of Epo production 
in HepG2 cells and isolated perfused rat kidneys. 
3.3. Effect of RA on serum Epo concentrations in vitamin 
A-depleted rats 
To know the in vivo effect of RA on Epo production, 
vitamin A-depleted rats were used, because the retinoid 
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Fig. 3. Effect of RA on Epo mRNA contents in HepG2 cells. 
(A) Schematic drawing for a competitive RT-PCR. A horizontal col- 
umn represents a part of the human Epo genomic DNA. Horizontal 
arrows show sense (Epo-A) and antisense (Epo-B) primers. Represent- 
ing nucleotide numbers are based on the reference 30. Epo genomic 
DNA and Epo cDNA were amplified to yield 619 bp and 485 bp 
fragments, respectively. (B) After preculture of the cells to deplete RA 
as described in section 2, the cells were cultured in 100-mm dishes in 
RA-depleted FCS containing 100 nM RA for 24 h at 1% 0,. The 
indicated amount of Epo genomic DNA was added in each PCR reac- 
tion as a competitor. Ratios of the two bands (619 bp of Epo genomic 
DNA/485 bp of Epo cDNA) are presented in each lane. Each photo- 
graph shows representative data in triplicate cultures. 
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Fig. 4. RA elevates the serum Epo concentration in vitamin-A depleted 
rats. Vitamin A-depleted rats were prepared [3 11. Male weaning rats of 
the Wistar strain (3-week-old) were depleted of endogenous retinoids 
by feeding them on a vitamin A-deficient diet, in which the other 
nutrients were sufficient to support normal growth based on the AIN- 
76 diet. After 30 days of depletion, these vitamin A-depleted rats were 
given intragastrically 100 fig RA in 0.2 ml soybean oil (dark-shaded 
columns) or 0.2 ml soybean oil alone (a white column), and were 
sacrificed after 4 h or 24 h. Epo in the sera was assayed. Four rats were 
used for the 24 h experiment and six rats were used for the 4 h experi- 
ments. Each value represents the mean f SD. The asterisk represents 
significant difference from the vitamin A-depleted rats given soybean 
oil alone (P < 0.01). 
pool in the normal rats interferes with the examination 
of the effect of RA. After the breeding of rats with a 
vitamin A-deficient diet, RA was given intragastrically. 
The Epo concentration in rat serum increased (P c 0.01) 
4 h after RA administration, and returned to the original 
level within 24 h when exogenous RA was almost com- 
pletely catabolized (Fig. 4). These findings suggest hat 
RA stimulates Epo production in Epo-producing cells in 
vivo. The RA-induced increase in serum Epo, however, 
was too small and our attempt to find whether RA ele- 
vated Epo mRNA in kidney or liver was unsuccessful. 
We could identify Epo mRNA in these tissues but the 
RA-induced changes in its level were within experimental 
error. Although hypoxia is a signal that can stimulate 
Epo production most intensively, RA may play an im- 
portant role in the maintenance of an Epo level appropri- 
ate to the day-to-day production of red blood cells under 
normal, steady-state conditions. 
Epo has been thought to exclusively act on erythroid 
cells in vivo but there is growing evidence that neurons 
respond to Epo [33,34]. A novel site for Epo production 
in brain has been found [35,36]; astrocytes produce Epo 
[36]. It is of interest whether RA stimulates brain Epo 
production, which is in progress using cloned astrocytes. 
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